Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory

Cardiovascular diseases keep being the leading cause of mortality in Spain. Efforts should be intensified to identify new risk factors that may contribute to increasing cardiovascular risk. Lipoprotein(a) (Lp(a)) has been associated with a higher risk for developing aortic valve stenosis, heart failure, ischemic stroke, ischemic heart disease and peripheral arterial disease. Hyperlipoproteinemia(a) is a common health problem. Between 10 and 30 % of the world population have Lp(a) values exceeding 50 mg/dL. The scientific evidence provided in the recent years confirms an independent association between Lp(a) and the risk for having an arteriosclerotic cardiovascular event. This finding, added to the emergence of new specific therapies for reducing Lp(a) has raised interest in the quantification of this lipoprotein. The objective of this paper was to perform a review of the evidence available to identify the patients who will benefit from undergoing Lp(a) testing and determine the recommended quantification methods, the desirable concentrations, and the role of Lp(a) determination in reclassifying the cardiovascular risk of patients.

Authors

Institutions

Publication Details

Journal
Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
Published
2025-03-01
DOI
https://doi.org/10.1515/almed-2025-0034
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory

Núria Amigó, José Puzo, Beatriz Candás Estébanez, Carla Fernández Prendes et al.
Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
Lipoproteins and Cardiovascular Health
article

Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory

Núria Amigó, José Puzo, Beatriz Candás Estébanez, Carla Fernández Prendes, María Martín Palencia, Irene González Martínez, Pilar Calmarza, Teresa Arrobas Velilla, María José Castro, Carlos Romero, Silvia Camós Anguila, David Ceacero
article en

Abstract

Cardiovascular diseases keep being the leading cause of mortality in Spain. Efforts should be intensified to identify new risk factors that may contribute to increasing cardiovascular risk. Lipoprotein(a) (Lp(a)) has been associated with a higher risk for developing aortic valve stenosis, heart failure, ischemic stroke, ischemic heart disease and peripheral arterial disease. Hyperlipoproteinemia(a) is a common health problem. Between 10 and 30 % of the world population have Lp(a) values exceeding 50 mg/dL. The scientific evidence provided in the recent years confirms an independent association between Lp(a) and the risk for having an arteriosclerotic cardiovascular event. This finding, added to the emergence of new specific therapies for reducing Lp(a) has raised interest in the quantification of this lipoprotein. The objective of this paper was to perform a review of the evidence available to identify the patients who will benefit from undergoing Lp(a) testing and determine the recommended quantification methods, the desirable concentrations, and the role of Lp(a) determination in reclassifying the cardiovascular risk of patients.

Advances in Laboratory Medicine / Avances en Medicina de LaboratorioVol. 6(1)
Universitat de Vic - Universitat Central de Catalunya (ES), Instituto de Salud Carlos III (ES), Bellvitge University Hospital (ES), Research Institute Hospital 12 de Octubre (ES), Hospital Universitario Virgen Macarena (ES), Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES), Centro de Investigación en Red en Enfermedades Cardiovasculares (ES), Hospital Universitario Miguel Servet (ES), Instituto de Investigación Sanitaria Aragón (ES), Comunidad de Madrid (ES), Hospital General Universitario de Albacete (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Universitari de Girona Doctor Josep Trueta (ES), Hospital General San Jorge (ES), Universidad de Burgos (ES), Universitat Rovira i Virgili (ES)
Openalex Percentile: Top 93%
Lipoproteins and Cardiovascular Health
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.